Home | Business News | Browse by Publication | B | Biotech Business

REGENERX COMPLETES ENROLLMENT OF PHASE IA FOR HEART DRUG.

Publication: Biotech Business
Publication Date: 01-AUG-08
Format: Online
Delivery: Immediate Online Access

Article Excerpt
RegeneRx Biopharmaceuticals, Bethesda, Md., (AMEX:RGN) has completed enrollment and dosing of 40 healthy subjects for its Phase IA clinical trial testing RGN-352, an injectable formulation of T?4 for potential use in treating acute myocardial infarction patients (AMI or heart attack). The trial includes four groups of ten subjects each to assess the safety of escalating doses of RGN-352 injected into the blood stream. To date, there have been no significant drug-related adverse events. A final analysis and report will be...

Access Full Article, Compliments of Goliath



More articles from Biotech Business
APP PHARMACEUTICALS GETS APPROVALS FOR ADDITIONAL DOSAGES., August 01, 2008

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.